Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus

Table 2 Hemodynamic responses to DPP-4 inhibitors in patients with type 2 diabetes during treatment

N = 51	Week 0	Week 4	Week 8	Week 12	P
AiX@75	24.5 (9.3)	23.4 (10.5)	23.2 (7.9)	22.3 (6.8)	0.031
cSBP (mmHg)	131.8 (12.9)	128.6 (11.7)	124.6 (10.5)^a	119.5 (15.4)^a	0.001
cDBP (mmHg)	79.8 (6.8)	79.0 (8.2)	77.5 (11.0)	77.2 (14.1)	0.003
oSBP (mmHg)	141.8 (10.2)	139.1 (13.1)	135.1 (12.1)^a	131.8 (18.3)^a	0.042
oDBP (mmHg)	82.7 (1.9)	78.8 (12.4)	78.2 (7.6)	75.6 (10.5)	0.001

Data are expressed by mean (SD), AIX@75 augumentation index standardized for 75 beats per minute, cSBP central systolic blood pressure, cDBP central diastolic blood pressure, oSBP office systolic blood pressure, oDBP office diastolic blood pressure
^a The large decrease in the cSBP and oSBP as well as STD which is large might be due to three patients who experienced a high cSBP reduction as follows: 126–112, 133–116 and 146–124 mmHg while for the same patients the oSBP were: 132–111, 144–133 and 154–123 mmH

ISSN: 1758-5996